secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000917520-25-000069
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY
--------------------------------------------------------------------------------

- Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
- GAAP net loss $484.1M includes $511M goodwill impairment; adjusted EBITDA $71.2M (17.1% margin) vs $83.8M (20.0%) prior year.
- Full-year 2025 revenue guidance narrowed to $1.655B–$1.680B; adj EPS reaffirmed at $2.19–$2.29.
- Net debt $1.59B; total leverage ratio 4.5x; liquidity ~$1.14B including $254M cash and short-term investments.
- Completed all manufacturing site baseline assessments under Compliance Master Plan; no new shipping holds in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000069/0000917520-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000069/iart-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer